Ivermectin (IVM), a lipid-based anthelmintic agent, effectively manages both endoparasites and ectoparasites. There is a clear association between instances of Ivermectin (IVM) overdoses, concerns over its effectiveness, and the emergence of resistance. The co-administration of Ivermectin (IVM) and Ascorbic Acid (AA) in the treatment groups exhibits a significant improvement at elevated dosages. The main objective of this study was to assess the possible interaction or viability of co-administering ascorbic acid and ivermectin at a uniform dosage. The infrared spectra of Ivermectin and ascorbic acid were analyzed in the spectral region of 4000 cm-1 to 400 cm-1. The spectra were compared to reference peaks that corresponded to specific functional groups. The visual characteristics of the band's performance may exhibit variation contingent upon the number of bands participating. The primary purpose of this study was to assess the possible interaction between ivermectin and ascorbic acid in order to ascertain the need and viability of polypharmacy or a combination of these two medications in varying proportions. The ratios examined in this study included 1:1, 1:3, 1:5, 3:1, and 5:1. The investigation incorporated evidence regarding the possibility for interaction between ivermectin and ascorbic acid, whether provided concurrently or in combination.
